Document:

EX-10.1

	 	 	 	 	 
	
 
	 	X

:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	
 
	 	:
	 	

	SUPREME COURT OF THE STATE OF NEW YORK COUNTY OF NEW

YORK

	 	:

:

X
	 	Index No. 06/603 842

IAS Part 53

J.S.C. Charles E. Ramos
	 

	 	

	 	

	 
	 	 	 	 
	Maxine Babus, Derivatively On Behalf Of Nominal Defendant

LORAL SPACE & COMMUNICATIONS INC.,

Plaintiff,

vs.

MICHAEL B. TARGOFF, MARK H. RACHESKY, M.D., SAI

DEVABHAKTUNI, HAL GOLDSTEIN, JOHN D. HARKEY, JR., DEAN A.

OLMSTEAD, ARTHUR L. SIMON, and JOHN P. STENBIT,

Defendants,

and

LORAL SPACE & COMMUNICATIONS INC.,

Nominal Defendant.

	 	

	 	

	 

	 	

	 	

MEMORANDUM OF UNDERSTANDING

The undersigned parties to the shareholder derivative action filed on November 3, 2006 in the
Supreme Court of the State of New York, County of New York (the “Court”), captioned Babus v.
Targoff, et al., Index No. 06/603 842 (the “Lawsuit”), and MHR Capital Partners Master Account LP
(“Master Account”), MHR Capital Partners (100) LP (“Capital Partners (100)”), MHR Institutional
Partners II LP (“Institutional Partners II”), MHR Institutional Partners IIA LP (“Institutional
Partners IIA”) and MHR Institutional Partners III LP (“Institutional Partners III” and together
with Master Account, Capital Partners (100), Institutional Partners II, Institutional Partners IIA
and Institutional Partners III, the “MHR Funds”) have reached an agreement in principle providing
for the settlement of the causes of action set forth in the Shareholder Derivative Complaint on the
terms and subject to the conditions set forth in this Memorandum of Understanding (“MOU”):

WHEREAS, the Lawsuit is brought by shareholder Maxine Babus (“Plaintiff”) and asserts
derivative claims on behalf of Loral Space & Communications Inc. (“Loral” or the “Company”) against
Michael B. Targoff, Mark H. Rachesky, M.D., Sai Devabhaktuni, Hal Goldstein, John D. Harkey, Jr.,
Dean A. Olmstead, Arthur L. Simon and John P.

Stenbit (collectively, the “Individual Defendants”) who constitute Loral’s board of directors (the
“Board”);

WHEREAS, the Lawsuit alleges that the Individual Defendants breached their fiduciary duties,
including the fiduciary duty of loyalty, in connection with the Company’s agreement to sell to the
Company’s largest shareholder, MHR Fund Management LLC (“Fund Management”), approximately $300
million in shares (the “Preferred Shares”) of the Company’s Series A-1 Cumulative 7.50% Convertible
Preferred Stock, par value $.01 per share, and the Company’s Series B-1 Cumulative 7.50% Preferred
Stock, par value $.01 per share, pursuant to that certain Securities Purchase Agreement, dated as
of October 17, 2006, as amended and restated as of February 27, 2007 (the “SPA”), by and between
the Company and Fund Management;

WHEREAS, the Lawsuit seeks declaratory relief, preliminary and permanent equitable relief, and
monetary damages;

WHEREAS, on December 8, 2006, Plaintiff served a motion for expedited discovery on Loral and
the Individual Defendants (together, the “Defendants”). Defendants served their opposition to
Plaintiff’s motion on December 18, 2006, and Plaintiff served her reply on December 21, 2006. The
motion was scheduled for oral argument before the Court on January 3, 2007;

WHEREAS, the parties conferred prior to the hearing on January 2, 2007, and Plaintiff agreed
to withdraw her motion in exchange for Defendants’ agreement to produce the documents requested by
Plaintiff;

WHEREAS, as a result of the parties’ January 2, 2007 negotiation and subsequent discussions
concerning discovery, Defendants produced, and Plaintiff’s counsel have reviewed, non-public
documents over the past three months produced by Defendant’s counsel and interviewed the financial
advisor to the Special Committee of Loral’s Board;

WHEREAS, on January 2, 2007, Defendants served a motion to dismiss Plaintiff’s complaint
pursuant to CPLR 3211(a) for failure to adequately allege the futility of demand on Loral’s Board
and for failure to state a cause of action for breach of fiduciary duty;

WHEREAS, on or about February 12, 2007, Plaintiff’s counsel advised Defendants that it was
their intention to file an amended complaint incorporating the new factual allegations developed by
Plaintiff during discovery;

WHEREAS, between January 2, 2007 and the present, the parties and the MHR Funds, by and
through their respective counsel, have engaged in extensive arm’s-length and good faith discussions
regarding the possibility of settling the Lawsuit;

WHEREAS, on February 26, 2007, all other conditions having been satisfied, Loral obtained the
regulatory approvals required under the SPA to permit and require the consummation of the SPA, and
on February 27, 2007, Loral and the MHR Funds consummated the SPA;

WHEREAS, the parties and the MHR Funds have reached an agreement in principle concerning the
proposed settlement of the Lawsuit as set forth below;

WHEREAS, counsel for the parties and the MHR Funds believe that the proposed settlement is
fair, reasonable, adequate, and in the best interests of Loral;

WHEREAS, Defendants, to avoid the costs, disruption, and distraction of further litigation,
and without admitting the validity of any allegations made or causes of action asserted in the
Lawsuit, or any liability with respect thereto, have concluded that it is desirable that the causes
of action against them be settled on the terms reflected in this MOU;

NOW, THEREFORE, as a result of the foregoing and the negotiations among counsel, the parties
and the MHR Funds have agreed in principle to settle the Lawsuit on the terms and conditions set
forth below (the “Settlement”), subject to the approval of the Court:

1. a. The MHR Funds will pay to Loral $4 million in cash within five (5) business days of
obtaining Final Court Approval (as defined in paragraph 6 below); and

b. The MHR Funds will pay to Loral an amount in cash within five (5) business days following
the MHR Funds’ (which for purposes of this Section 1(b) shall be deemed to include any investment
partnerships controlled by Fund Management) actual receipt of net cash or cash equivalent proceeds
as set forth in this Section 1(b). In the event that the MHR Funds’ actual receipt of net cash or
cash equivalent proceeds from the sale by the MHR Funds of (A) any or all Preferred Shares, (B) any
shares, including any paid-in-kind dividends or Conversion Shares (as hereinafter defined) issued
in respect of and pursuant to the terms of such Preferred Shares, or (C) any securities issued or
delivered in exchange for or in respect of the securities referred to in clauses (A) and (B) above,
taken together with the aggregate amount actually received by the MHR Funds in cash or cash
equivalents for the securities referred to in clauses (A) and (B) above in consideration for any
prior sales of such securities, in one or more transactions, is in excess of an amount equal to the
product of:

(i) (X) $55 multiplied by (Y) the sum of the number of Preferred Shares issued on the Closing
Date, plus any other shares, including any paid-in-kind dividends, issued in respect and pursuant
to the terms thereof through the date of such sale, then the MHR Funds will pay (or cause the
payment) to Loral an amount in cash equal to $9.5 million;

(ii) (X) $70 multiplied by (Y) the sum of the number of Preferred Shares issued on the Closing
Date, plus any other shares, including any paid-in-kind dividends, issued in respect and pursuant
to the terms thereof through the date of such sale, then the MHR Funds will pay (or cause the
payment) to Loral an additional amount in cash equal to $8.5 million, such that the total amount of
all cash payments to Loral pursuant to this Section 1(b) will equal $18 million; and

(iii) (X) $80 multiplied by (Y) the sum of the number of Preferred Shares issued on the
Closing Date, plus any other shares issued, including any paid-in-kind dividends, in respect and
pursuant to the terms thereof through the date of such sale, then the MHR Funds will pay (or cause
the payment) to Loral an additional amount in cash equal to $8.5 million, such that the total
amount of all cash payments to Loral pursuant to this Section 1(b) will equal $26.5 million.

Any distribution of any securities referred to in this Section 1(b) by any of the MHR Funds to
any of their respective limited partners shall be deemed to be a sale for cash or cash equivalent
proceeds at the value determined by the MHR Funds in accordance with the applicable MHR Fund
partnership agreement.

“Conversion Shares” means the shares issued to the MHR Funds upon conversion of the Preferred
Shares or any other preferred shares issued, including any paid-in-kind dividends, in respect of
and pursuant to the terms of such Preferred Shares, and any replacement securities which the MHR
Funds actually receive from time to time in exchange for such Conversion Shares.

All calculations set forth in this Section 1(b) shall be subject to proportionate adjustment
to take into account any stock dividend, split, reverse split, combination, recapitalization or any
similar transaction affecting the common stock, par value $0.01, of the Company as provided for in
the Company’s Certificate of Incorporation. When used in connection with any preferred shares
referred to in clause (Y) of subsections (i), (ii) and (iii) of this Section 1(b), such number of
preferred shares shall be multiplied by the applicable Conversion Number at the time of such sale
for such preferred shares as defined in the applicable Certificate of Designation relating thereto.

All capitalized terms used in this paragraph 1(b) and not defined herein shall have the
meanings ascribed to them in the SPA and the exhibits thereto.

2. The Individual Defendants, Loral and the MHR Funds acknowledge that the benefits described
in paragraph 1 above are the exclusive result of Plaintiff’s prosecution of the Lawsuit on Loral’s
behalf.

3. Upon the execution of this MOU, Plaintiff’s counsel will promptly file an amended complaint
which shall include the MHR Funds, Fund Management, MHR Institutional Advisors LP, MHRM LP, MHRA
LP, MHR Institutional Advisors LLC (“Institutional Advisors”), MHR Advisors LLC (“Advisors”), MHR
Institutional Advisors II LLC (“Institutional Advisors II”), MHR Institutional Advisors III LLC
(“Institutional Advisors III”) and Mark H. Racheskey (in his capacity as the managing member of
Fund Management, Advisors, Institutional Advisors, Institutional Advisors II and Institutional
Advisors III) (collectively, “MHR”) as a defendant and shall be the complaint for purposes of this
Settlement.

4. The parties to the Lawsuit and the MHR Funds will use their best efforts to agree upon and
execute an appropriate stipulation of settlement (the “Stipulation”) and such other documentation
as may be required in order to obtain Final Court Approval of the Settlement and dismissal of the
Lawsuit upon the terms and conditions set forth in this MOU (collectively with the Stipulation, the
“Settlement Documents”). The Stipulation will expressly provide, inter alia, that: (a) all
Individual Defendants have denied, and continue to deny, that they have committed, attempted to
commit, or aided and abetted others in committing, any violations of law or engaged in any wrongful
acts; (b) the Defendants are entering into the Stipulation because the proposed Settlement would
eliminate the burden, expense and distraction associated with further litigation; (c) Plaintiff and
Plaintiff’s counsel, having made a thorough investigation of the facts, believe that the proposed
Settlement is fair, reasonable and adequate and in the best interests of Loral and its
shareholders; (d) neither this MOU, the Stipulation, nor any of their respective terms shall
constitute an admission or finding of wrongful conduct, acts or omissions on the part of any of the
Defendants or be admissible in any proceeding (other than for the purpose of enforcing their
terms); (e) judgment be entered by the Court dismissing the Lawsuit in its entirety with prejudice
and without costs to any party (except as provided in paragraph 8 below) and barring any causes of
action that have been or might have been brought in any court or forum by Loral or any Loral
shareholder on Loral’s behalf relating to or arising out of allegations made in the Lawsuit; and
(f) complete discharge, dismissal with prejudice, settlement and release of, and an injunction
barring, any and all claims, rights and causes of action, for damages, injunctive or equitable
relief, or any other remedies, whether based on federal, state, local, statutory or common law or
any other law, rule, or regulation, including, without limitation, known and unknown claims and
claims under New York and Delaware statutory and common law, federal and state securities laws and
claims under any federal or state law governing fiduciaries or the duties of fiduciaries, that have
been, could have been, or in the future might be or could be asserted in any form and in any forum
by Loral shareholders on behalf of Loral against Defendants, MHR, and any of their families, parent
entities, affiliates or subsidiaries and each and all of their respective past, present, or future
officers, directors, employees, attorneys, accountants, auditors, agents, investment bankers,
consultants, insurers, reinsurers, heirs, executors, personal representatives, estates,
administrators, predecessors, successors and assigns, and all entities managed or advised by MHR
(collectively, the “Released Persons”) relating to or arising out of the subject matters contained
in the complaints filed in the Lawsuit (the “Released Claims”). The Stipulation shall include a
waiver, to the extent permitted by law, of unknown claims, including a waiver of the provisions of
California Civil Code § 1542 and any similar provisions of the law of any other jurisdictions.

5. The parties to the Lawsuit will present the Settlement Documents to the Court as soon as
practicable for approval of the proposed Settlement and any notice of the proposed Settlement to
Loral shareholders required by the Court. Loral shall be responsible for and pay all costs and
expenses incident to such notice. The contents and manner of such notice shall be mutually agreed
upon by the parties to this MOU.

6. The parties to the Lawsuit will also use their best efforts to obtain Final Court Approval
of the Stipulation and Settlement, entry of final judgment, and dismissal of the Lawsuit with
prejudice as to all causes of action asserted or which could have been asserted against Defendants
and MHR in the Lawsuit and without costs to any party (other than counsel fees and expenses as
provided in paragraph 8 below). As used herein, “Final Court Approval” of the Settlement means
that the Court has entered an order approving the Settlement in accordance with the terms of the
Settlement Documents and that such order is finally affirmed on appeal or is no longer subject to
appeal.

7. The consummation of the Settlement is subject to: (a) the drafting and execution of the
Settlement Documents; (b) the completion by Plaintiff of confirmatory discovery in the Lawsuit
reasonably satisfactory to Plaintiff’s counsel; and (c) Final Court Approval of the Stipulation and
Settlement and dismissal of the Lawsuit in its entirety with prejudice and without awarding costs
to any party (except as provided in paragraph 8 below). Any information disclosed during the
course of confirmatory discovery may not be used for any purpose, except for pleadings and court
papers filed for the purpose of effectuating the Settlement. This MOU shall be null and void and of
no force and effect should any of the conditions set forth in this paragraph not be met or should
Plaintiff’s counsel reasonably determine, following confirmatory discovery, that the Settlement is
not fair and reasonable, and in that event, this MOU shall neither be deemed to prejudice in any
way the positions of the parties with respect to the Lawsuit nor entitle any party to recover any
costs or expenses incurred in connection with the implementation of this MOU.

8. Following the negotiation of the Settlement terms above, the parties negotiated at
arm’s-length and in good faith over the attorneys’ fees, costs and expenses to be awarded to
Plaintiff’s counsel subject to approval by the Court. Plaintiff’s Counsel have advised the
Defendants that they intend to apply to the Court for an award of attorneys’ fees and
reimbursements of expenses and disbursements, in an aggregate amount not to exceed (i) $1.5 million
in cash to be paid solely by Loral to the account of Rigrodsky & Long, P.A., as escrow agent of
Plaintiff’s counsel (“Rigrodsky”), within five (5) business days of Final Court Approval of the
Settlement and the fee award, and (ii) an additional amount not to exceed $250,000 promptly
following any payment made pursuant to each of Sections 1(b)(i), 1(b)(ii) and 1(b)(iii). Rigrodsky
shall be solely responsible for the distribution of Plaintiff’s attorneys’ fees, costs and
expenses. Loral shall have no responsibility or liability for any award of fees, costs and expenses
in excess of $2.25 million and neither the Defendants nor MHR shall have any responsibility or
liability for the allocation of the fees, costs and expense awards among Plaintiff’s counsel in the
Lawsuit. The court’s decision regarding award of attorneys’ fees, costs and expenses shall not
affect the validity or finality of the remaining terms of the Settlement.

9. Miscellaneous: (a) this MOU may be executed in counterparts by any of the signatories
hereto, including by fax or telecopy, and as so executed shall constitute one agreement; (b) this
MOU, the Stipulation and the Settlement contemplated by them shall be governed by and construed in
accordance with the laws of the State of New York without regard to New York conflict of laws
rules, and the Court shall have exclusive jurisdiction over any action or proceeding to enforce or
challenge the effect of this MOU, the Stipulation or the Settlement; (c) this MOU shall be binding
upon and inure to the benefit of the parties and their respective agents, attorneys, executors,
heirs, successors and assigns, subject to the conditions set forth herein; (d) each of the
attorneys executing this MOU represents that she or he has been duly empowered and authorized by
his/her respective client(s) to do so; (e) Plaintiff and her undersigned counsel represent and
warrant that none of the claims or causes of action asserted in the Lawsuit has been assigned,
encumbered or in any manner transferred in whole or in part; (f) neither the Individual Defendants
nor MHR (except as expressly provided herein) shall bear any responsibility for any payments under
this MOU, the Stipulation, or the Settlement, or any expenses, costs, damages or fees alleged or
incurred by Plaintiff or her attorneys, experts, advisors, agents or representatives; (g) the
provisions contained in this MOU, and any of the negotiations or proceedings connected with it,
shall not be deemed or construed as a presumption, concession or admission by any of the Individual
Defendants, Loral, or MHR of any breach of duty, liability, default or wrongdoing or as to any
facts or causes of action which were or could have been alleged or asserted in the Lawsuit, and
shall not be interpreted, construed, deemed, invoked, offered or received in evidence or otherwise
used by any person in the Lawsuit or in any other action or proceeding of any nature whatsoever;
and (h) this MOU contains the parties’ entire agreement on the subject hereof, and supersedes any
prior oral or written communications by the parties, and may be modified or amended only by a
writing signed by the signatories hereto.

10. By signing this MOU, Plaintiff’s counsel represents and warrants that Plaintiff was a
Loral shareholder at the time the Lawsuit was filed and is still a shareholder of Loral.

11. Pending consummation of the Settlement, Plaintiff shall not seek relief in any forum, or
take any action in the Lawsuit, and all proceedings in the Lawsuit or otherwise shall be stayed and
suspended, except (i) as to the confirmatory discovery discussed at paragraph 7 above and (ii) that
the parties shall take all such action and file such papers as are necessary and appropriate to
effect consummation and approval of the Settlement.

12. If any action or other proceeding is or has been filed in state or federal court asserting
claims that are related to the subject matter of the Lawsuit prior to Final Court Approval of the
Settlement, Plaintiff’s counsel shall reasonably cooperate with Defendants in obtaining the stay,
dismissal, or withdrawal of any such action, including joining in any motion to dismiss such action
to the extent such action is consistent with Plaintiff’s counsel’s fiduciary duties.

	 	 	 
	Dated: March 21, 2007

	 	FARUQI & FARUQI, LLP

BY: /s/ Nadeem Faruqi
	
 
	 	 
	
 
	 	NADEEM FARUQI

BETH A. KELLER

369 Lexington Avenue, 10th Floor

New York, NY 10017 Telephone: 212/983-9330

Facsimile: 212/983-9331

Attorneys for Plaintiff
	 
	 	 
	Dated: March 21, 2007

	 	RIGRODSKY & LONG, P.A.

BY: /s/ Seth D. Rigrodsky
	
 
	 	 
	
 
	 	SETH D. RIGRODSKY

BRIAN D. LONG

919 North Market Street, Suite 980 Wilmington,

DE 19801

Telephone: 302/295-5310

Facsimile: 302/654-7530

Attorneys for Plaintiff
	 
	 	 
	Dated: March 21, 2007

	 	WILLKIE FARR & GALLAGHER LLP

BY: /s/ Francis J. Menton, Jr.
	
 
	 	 
	
 
	 	FRANCIS J. MENTON, JR.

RUSSELL D. MORRIS

DANIEL M. BURSTEIN

787 Seventh Avenue

New York, New York 10019 Telephone:
	
 
	 	212/728-8000 Facsimile: 212/728-8111

Attorneys for Michael Targoff, Dean

Olmstead and John Stenbit
	 
	 	 
	Dated: March 21, 2007

	 	STROOCK & STROOCK & LAVAN LLP

BY: /s/ Melvin A. Brosterman
	
 
	 	 
	
 
	 	MELVIN A. BROSTERMAN

RYAN M. PAPIR

180 Maiden Lane

New York, New York 10038 Telephone:
	
 
	 	212/806-5400 Facsimile: 212/806-6006

Attorneys for MHR Capital Partners Master

Account LP, MHR Capital Partners (100) LP, MHR

Institutional Partners II LP, MHR

Institutional Partners IIA LP, MHR

Institutional Partners III LP, Mark Rachesky,

Sai Devabhaktuni, and Hal Goldstein
	 
	 	 
	Dated: March 21, 2007

	 	KING & SPALDING LLP

BY: /s/ Richard A. Cirillo
	
 
	 	 
	
 
	 	RICHARD A. CIRILLO

1185 Avenue of the Americas

New York, NY 10036

Telephone: 212/556-2100 Facsimile: 212/556-2222

Attorneys for John D. Harkey, Jr. and Arthur

L. Simon
	 
	 	 
	Dated: March 21, 2007

	 	TRACHTENBERG RODES & FRIEDBERG LLP

BY: /s/ Leonard A. Rodes
	
 
	 	 
	
 
	 	LEONARD A. RODES

545 Fifth Avenue

New York, New York 10017

Telephone: 212/972-2929

Facsimile: 212/972-7581

Attorneys for Loral Space &

Communications Inc.EX-10.63

	 	 	 
	US$4,000,000

	 	March 21, 2007

New York, New York

PROMISSORY NOTE

For value received, and on the terms and subject to the conditions set forth herein, STAAR
Surgical Company, a corporation formed and existing under the laws of the State of Delaware (the
“Company”), HEREBY PROMISES TO PAY to Broadwood Partners, L.P. (the “Noteholder”), on the Maturity
Date (as defined below) the principal sum of US$4,000,000 (the “Loan”), plus any unpaid interest
accrued thereon, or such lesser amount as shall be equal to the unpaid principal amount of the Loan
plus such interest. The Company hereby promises to make principal repayments and to pay interest
on the dates and at the rate or rates provided for herein.

The Noteholder will receive warrants (the “Warrants”) issued hereunder and under that certain
Warrant Agreement dated the date hereof between the Company and the Noteholder (the “Warrant
Agreement”) to purchase that number of shares of common stock, par value $.01 per share (the
“Common Stock”) as set forth herein and in the Warrant Agreement at an exercise price of $6.00 (the
“Exercise Price”) per share (the “Warrant Shares”).

SECTION 1. Certain Terms Defined. The following terms for all purposes of this Note shall
have the respective meanings specified below.

“Business Day” means any day except a Saturday, Sunday or other day on which commercial banks
in New York, New York are authorized by law to close.

“Change of Control” has the meaning set forth in the Company’s Credit and Security Agreement,
dated June 8, 2006 between the Company and Wells Fargo Bank, National Association, provided that no
Change of Control shall be deemed to occur as a result of (i) acquisition of securities of the
Company by the Noteholder or its affiliates, or (ii) changes in the Board of Directors resulting
from annual uncontested elections.

“Commission Documents” has the meaning set forth in Section 8(e).

“Common Stock” has the meaning set forth in the introductory paragraphs.

“Company” has the meaning set forth in the introductory paragraphs.

“Equity Securities” has the meaning set forth in Section 10(j).

“Event of Default” has the meaning set forth in Section 7.

“Exchange Act” has the meaning set forth in Section 8(e).

“Exercise Price” has the meaning set forth in the introductory paragraphs.

“Form 10-K” has the meaning set forth in Section 8(e).

“Form 10-Q” has the meaning set forth in Section 8(e).

“GAAP” has the meaning set forth in Section 8(e).

“Indebtedness” has the meaning set forth in Section 8(j).

“Intellectual Property Rights” has the meaning set forth in Section 8(q).

“Maximum Number of Shares” has the meaning set forth in Section 5.

“Loan” has the meaning set forth in the introductory paragraphs.

“Maturity Date” means March 21, 2010, or such earlier date as may be provided in Section 7;
provided that if any such date is not a Business Day, then such date shall be the next succeeding
Business Day.

“Note” shall mean this Promissory Note as amended, from time to time, in accordance with the
terms hereof.

	 	 	 
	“Notice” has the meaning set forth in Section 10(j).

	 
	 	 
	“Noteholder” has the meaning set forth in the introductory paragraphs.

	 
	 	 
	“Securities Act” has the meaning set forth in Section 8(w).

	 
	 	 
	“Subsidiary” has the meaning set forth in Section 8(f).

	 
	 	 
	“Warrants” has the meaning set forth in the introductory paragraphs.

	 
	 	 
	“Warrant Agreement” has the meaning set forth in the introductory paragraphs.

	 
	 	 
	“Warrant Shares” has the meaning set forth in the introductory paragraphs.

	 
	 	 
	SECTION 2.

	 	Loan Drawdown.

The Noteholder shall make the Loan to the Company within twenty four hours after the execution
of this Note.

SECTION 3. Maturity Of the Loan.

The Loan shall mature, and the principal amount thereof shall become immediately due and
payable (together with unpaid interest accrued thereon) on the Maturity Date.

SECTION 4. Interest Payments.

The unpaid principal amount of the Loan outstanding shall bear interest at a rate equal to ten
percent (10%) per annum. Notwithstanding the foregoing, upon an Event of Default, this Note shall
bear interest on and after the date of such Event of Default at a rate equal to the lesser of (i)
the maximum interest rate permitted by applicable law and (ii) 20%.

Interest shall be payable quarterly in arrears on the last day of the Company’s fiscal quarter
(or if any such day is not a Business Day, then on the next succeeding Business Day) provided,
however, the first interest payment shall not be due until June 30, 2007. Interest shall be
computed on the basis of a year of 365 days and paid for the actual number of days elapsed.

SECTION 5. Warrants.

So long as this Note shall remain outstanding the Company shall, in addition to the Warrants
issued under the Warrant Agreement, issue Warrants to the Noteholder on each of the following dates
in an amount equal to the “Maximum Number of Shares” set forth opposite such date times the
fraction resulting from the then outstanding principal balance on this Note divided by $4,000,000.

	 	 	 	 	 
	Date	 	Maximum Number of Shares
	6/30/07

	 	 	30,000	 
	 
	 	 	 	 
	9/30/07

	 	 	30,000	 
	 
	 	 	 	 
	12/31/07

	 	 	31,500	 
	 
	 	 	 	 
	3/31/08

	 	 	31,500	 
	 
	 	 	 	 
	6/30/08

	 	 	35,000	 
	 
	 	 	 	 
	9/30/08

	 	 	35,000	 
	 
	 	 	 	 
	12/31/08

	 	 	38,500	 
	 
	 	 	 	 
	3/31/09

	 	 	38,500	 
	 
	 	 	 	 
	6/30/09

	 	 	42,000	 
	 
	 	 	 	 
	9/30/09

	 	 	42,000	 
	 
	 	 	 	 
	12/31/09

	 	 	45,500	 
	 
	 	 	 	 
	3/21/10

	 	 	45,500	 

Except for the amount of Warrants and the date of issuance set forth above, the Warrants
issued under this Section 5 shall have all of the same terms and conditions (including, without
limitation, Exercise Price, term and adjustment mechanisms) as the Warrants issued under the
Warrant Agreement.

SECTION 6. Prepayments.

(a) Optional Prepayments. The Company may prepay the Loan, upon thirty (30) days prior
written notice to the Noteholder, in whole or in part at any time or from time to time without
penalty or premium by paying the principal amount to be prepaid together with accrued interest
thereon to the date of prepayment. Any such prepayments made under this Section 6 shall be in
minimum increments of $400,000.

(b) Mandatory Prepayments. The Company shall immediately repay the Loan, plus any unpaid
interest accrued thereon upon a Change of Control.

SECTION 7. General Provisions As To Payments.

All payments of principal and interest on the Loan by the Company hereunder shall be made not
later than 12:00 Noon (New York City time) on the date when due either by cashier’s check,
certified check or by wire transfer of immediately available funds to the Noteholder’s account at a
bank in the United States specified by the Noteholder in writing to the Company without reduction
by reason of any set-off or counterclaim.

SECTION 8. Events Of Default.

Each of the following events shall constitute an “Event of Default”:

(a) the principal of the Loan shall not be paid when due;

(b) any interest on the Loan shall not be paid within five (5) Business Days of when it was
due;

(c) the Company breaches any covenant hereunder and such breach is not cured within thirty
(30) days after notice from the Noteholder;

(d) any representation or warranty of the Company made in this Note shall be incorrect when
made in any material respect;

(e) the Company or any Subsidiary shall default in the payment when due (subject to any
applicable grace period), whether by acceleration or otherwise, of any material Indebtedness of the
Company or any Subsidiary involving the borrowing of money or the extension of credit in excess of
$500,000, or a default shall occur in the performance or observance of any obligation or condition
with respect to such Indebtedness if the effect of such default is to accelerate the maturity of
any such Indebtedness, or such default shall continue unremedied for any applicable period of time
sufficient to permit the holder or holders of such Indebtedness, or any trustee or agent for such
holders, to cause such Indebtedness to become due and payable prior to its expressed maturity;

(f) any judgment or order for the payment of money in excess of $500,000 shall be rendered
against the Company or any Subsidiary, shall remain unpaid, and shall not be covered by insurance;

(g) a court shall enter a decree or order for relief in respect of the Company or any
Subsidiary in an involuntary case under any applicable bankruptcy, insolvency or other similar law
now or hereafter in effect, or appointing a receiver, liquidator, assignee, custodian, trustee,
sequestrator (or similar official) of the Company or any Subsidiary or for any substantial part of
the property of the Company or any Subsidiary or ordering the winding up or liquidation of the
affairs of the Company or any Subsidiary, and such decree or order shall remain unstayed and in
effect for a period of 60 consecutive days; or

(h) the Company or any Subsidiary shall commence a voluntary case under any applicable
bankruptcy, insolvency or other similar law now or hereafter in effect, or consent to the entry of
an order for relief in an involuntary case under any such law, or consent to the appointment or
taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar
official) of the Company or any Subsidiary or for any substantial part of the property of the
Company or any Subsidiary, or the Company or any Subsidiary shall make any general assignment for
the benefit of creditors.

If an Event of Default described in (g) or (h) above shall occur, the principal of and accrued
interest on the Loan shall become immediately due and payable without any declaration or other act
on the part of the Noteholder. Immediately upon the occurrence of any Event of Default described
in (g) or (h) above, or upon failure to pay this Note on the Maturity Date, the Noteholder, without
any notice to the Company, which notice is expressly waived by the Company, may proceed to protect,
enforce, exercise and pursue any and all rights and remedies available to the Noteholder under this
Note, or at law or in equity.

If any Event of Default in (a) – (f) above shall occur for any reason, whether voluntary or
involuntary, and be continuing, the Noteholder may by notice to the Company declare all or any
portion of the outstanding principal amount of the Loan to be due and payable, whereupon the full
unpaid amount of the Loan which shall be so declared due and payable shall be and become
immediately due and payable without further notice, demand or presentment.

SECTION 9. Representations.

The Company hereby represents and warrants to the Noteholder, as follows:

(a) The Company is a corporation duly incorporated, validly existing and in good standing
under the laws of the State of Delaware and has the requisite corporate power to own, lease and
operate its properties and assets and to conduct its business as it is now being conducted. The
Company does not have any Subsidiaries except as set forth on Schedule 1 hereto. Each
Subsidiary is a corporation duly incorporated, validly existing and in good standing under the laws
of its jurisdiction of organization and has the requisite corporate power to own, lease and operate
its properties and assets and to conduct its business as it is now being conducted. The Company
and each such Subsidiary is duly qualified as a foreign corporation to do business and is in good
standing in every jurisdiction in which the nature of the business conducted or property owned by
it makes such qualification necessary.

(b) The Company has the requisite legal and corporate power and authority to enter into, issue
and perform this Note and the Warrant Agreement in accordance with the terms hereof and thereof.
The execution, delivery and performance of this Note and the Warrant Agreement by the Company and
the consummation by it of the transactions contemplated hereby or thereby have been duly and
validly authorized by all necessary corporate action, and no further consent or authorization of
the Company, its board of directors or stockholders is required. When executed and delivered by
the Company, this Note and the Warrant Agreement shall constitute valid and binding obligations of
the Company enforceable against the Company in accordance with its terms, except as such
enforceability may be limited by applicable bankruptcy, reorganization, moratorium, liquidation,
conservatorship, receivership or similar laws relating to, or affecting generally the enforcement
of, creditor’s rights and remedies or by other equitable principles of general application.

(c) The execution, delivery and performance of this Note, the Warrant Agreement and the
consummation by the Company of the transactions contemplated hereby or thereby, do not and will not
(i) violate or conflict with any provision of the Company’s certificate of incorporation or bylaws,
each as amended to date, or any Subsidiary’s comparable charter documents, (ii) conflict with, or
constitute a default (or an event which with notice or lapse of time or both would become a
default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond, license, lease
agreement, instrument or obligation to which the Company or any of its Subsidiaries is a party or
by which the Company or any of its Subsidiaries’ respective properties or assets are bound, or
(iii) result in a violation of any federal, state, local or foreign statute, rule, regulation,
order, judgment or decree (including federal and state securities laws and regulations) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any
of its Subsidiaries are bound or affected. Neither the Company nor any of its Subsidiaries is
required under federal, state, foreign or local law, rule or regulation to obtain any consent,
authorization or order of, or make any filing or registration with, any court or governmental
agency in order for it to execute, deliver or perform any of its obligations under this Note or
Warrant Agreement.

(d) The Company is not required to obtain any consent, authorization or order of, or make any
filing or registration with, any court, governmental agency or any regulatory or self-regulatory
agency or any other person in order for it to execute, deliver or perform any of its obligations
under or contemplated by this Note or Warrant Agreement, in each case in accordance with the terms
hereof. All consents, authorizations, orders, filings and registrations which the Company is
required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to
the date hereof.

(e) The common stock of the Company is registered pursuant to Section 12(b) or 12(g) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), and except for the Company’s 10-K
for the year ended December 29, 2006, the Company has timely filed all reports, schedules, forms,
statements and other documents required to be filed by it with the Commission pursuant to the
reporting requirements of the Exchange Act (all of the foregoing including filings incorporated by
reference therein being referred to herein as the “Commission Documents”). At the times of their
respective filings, the Form 10-K for the fiscal year ended December 30, 2005 (the “Form 10-K”) and
each subsequently filed Form 10-Q (collectively, the “Form 10-Q”) complied in all material respects
with the requirements of the Exchange Act and the rules and regulations of the Commission
promulgated thereunder and other federal, state and local laws, rules and regulations applicable to
such documents, and the Form 10-Q and Form 10-K did not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading.
The consolidated financial statements of the Company included in the Commission Documents complied
as to form in all material respects with applicable accounting requirements and the published rules
and regulations of the Commission or other applicable rules and regulations with respect thereto.
Such consolidated financial statements have been prepared in accordance with generally accepted
accounting principles (“GAAP”) applied on a consistent basis during the periods involved (except
(i) as may be otherwise indicated in such consolidated financial statements or the notes thereto or
(ii) in the case of unaudited interim statements, to the extent they may not include footnotes or
may be condensed or summary statements), and fairly present in all material respects the
consolidated financial position of the Company and its Subsidiaries as of the dates thereof and the
results of operations and cash flows for the periods then ended (subject, in the case of unaudited
statements, to normal year-end audit adjustments).

(f) Schedule 1 hereto sets forth each Subsidiary of the Company, showing the
jurisdiction of its incorporation or organization and showing the percentage of each person’s
ownership of the outstanding stock or other interests of such Subsidiary. For the purposes of this
Agreement, “Subsidiary” shall mean any corporation or other entity of which at least a majority of
the securities or other ownership interest having ordinary voting power (absolutely or
contingently) for the election of directors or other persons performing similar functions are at
the time owned directly or indirectly by the Company and/or any of its other Subsidiaries. All of
the outstanding shares of capital stock of each Subsidiary have been duly authorized and validly
issued, and are fully paid and nonassessable. There are no outstanding preemptive, conversion or
other rights, options, warrants or agreements granted or issued by or binding upon any Subsidiary
for the purchase or acquisition of any shares of capital stock of any Subsidiary or any other
securities convertible into, exchangeable for or evidencing the rights to subscribe for any shares
of such capital stock. Neither the Company nor any Subsidiary is subject to any obligation
(contingent or otherwise) to repurchase or otherwise acquire or retire any shares of the capital
stock of any Subsidiary or any convertible securities, rights, warrants or options of the type
described in the preceding sentence. Except as set forth in the Commission Documents, neither the
Company nor any Subsidiary is party to, nor has any knowledge of, any agreement restricting the
voting or transfer of any shares of the capital stock of any Subsidiary.

(g) Except as set forth in the Commission Documents or set forth in the 8-K to be filed by the
Company on March 21, 2007, since December 30, 2005, the Company has not experienced or suffered any
material adverse effect and the Company is not aware of any fact or circumstance that is reasonably
likely to have a material adverse effect on the Company.

(h) Except as set forth in the Commission Documents, neither the Company nor any of its
Subsidiaries has incurred any liabilities, obligations, claims or losses (whether liquidated or
unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) other than those
incurred in the ordinary course of the Company’s or its Subsidiaries respective businesses.

(i) Since December 30, 2005, except for the circumstances described on Schedule 2
hereto, no event or circumstance has occurred or exists with respect to the Company or its
Subsidiaries or their respective businesses, properties, prospects, operations or financial
condition, which, under applicable law, rule or regulation, requires public disclosure or
announcement by the Company but which has not been so publicly announced or disclosed.

(j) Except as set forth in the Commission Documents, neither the Company nor any Subsidiary
has any outstanding secured or unsecured Indebtedness. For the purposes of this Agreement,
“Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed in excess of
$100,000 (other than trade accounts payable incurred in the ordinary course of business) and (b)
all guaranties, endorsements and other contingent obligations in respect of Indebtedness of others,
whether or not the same are or should be reflected in the Company’s balance sheet (or the notes
thereto).

(k) Except as set forth in the Commission Documents, there is no Indebtedness of the Company
that is senior to or ranks pari passu with this Note in right of payment, whether with respect of
payment of redemptions, interest, damages or upon liquidation or dissolution or otherwise.

(l) Except as set forth in the Commission Documents, each of the Company and the Subsidiaries
has good and valid title to all of its real and personal property, free and clear of any mortgages,
pledges, charges, liens, security interests or other encumbrances. Any leases of the Company and
each of its Subsidiaries are valid and subsisting and in full force and effect.

(m) The Company and the Subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as management of the Company
believes to be prudent and customary in the businesses in which the Company and its Subsidiaries
are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage
sought or applied for and neither the Company nor any such Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business at
a cost that would not have a material adverse effect.

(n) Except as set forth in the Commission Documents, (i) there is no action, suit, claim,
investigation, arbitration, alternate dispute resolution proceeding or other proceeding pending or,
to the knowledge of the Company, threatened against the Company or any Subsidiary which questions
the validity of this Note or any of the transactions contemplated hereby or any action taken or to
be taken pursuant hereto, (ii) there is no action, suit, claim, investigation, arbitration,
alternate dispute resolution proceeding or other proceeding pending or, to the knowledge of the
Company, threatened against or involving the Company, any Subsidiary or any of their respective
properties or assets and (iii) there are no outstanding orders, judgments, injunctions, awards or
decrees of any court, arbitrator or governmental or regulatory body against the Company or any
Subsidiary or any officers or directors of the Company or Subsidiary in their capacities as such.

(o) Except as set forth in the Commission Documents, (i) the business of the Company and the
Subsidiaries has been and is presently being conducted in compliance with all applicable federal,
state and local governmental laws, rules, regulations and ordinances and (ii) the Company and each
of its Subsidiaries have all franchises, permits, licenses, consents and other governmental or
regulatory authorizations and approvals necessary for the conduct of its business as now being
conducted by it.

(p) Except as set forth in the Commission Documents, (i) the Company and each of the
Subsidiaries has accurately prepared and filed all federal, state and other tax returns required by
law to be filed by it, has paid or made provisions for the payment of all taxes shown to be due and
all additional assessments, and adequate provisions have been and are reflected in the consolidated
financial statements of the Company and the Subsidiaries for all current taxes and other charges to
which the Company or any Subsidiary is subject and which are not currently due and payable. The
Company has no knowledge of any additional assessments, adjustments or contingent tax liability
(whether federal or state) of any nature whatsoever, whether pending or threatened against the
Company or any Subsidiary for any period, nor of any basis for any such assessment, adjustment or
contingency.

(q) The Company and the Subsidiaries own or possess adequate rights or licenses to use all
trademarks, service marks, and all applications and registrations therefor, trade names, patents,
patent rights, copyrights, original works of authorship, inventions, licenses, approvals,
governmental authorizations, trade secrets and other intellectual property rights (“Intellectual
Property Rights”) necessary to conduct their respective businesses as now conducted. Except as
disclosed in the Commission Documents, none of the Company’s Intellectual Property Rights have
expired or terminated, or are expected to expire or terminate, within two years from the date of
this Agreement. The Company does not have any knowledge of any material infringement by the
Company or its Subsidiaries of Intellectual Property Rights of others. There is no material claim,
action or proceeding pending, or to the knowledge of the Company, being threatened, against the
Company or its Subsidiaries regarding its Intellectual Property Rights. The Company is unaware of
any material facts or circumstances which might give rise to any of the foregoing infringements or
claims, actions or proceedings. The Company and its Subsidiaries have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their material Intellectual
Property Rights.

(r) Except as disclosed in the Commission Documents, the Company and each of its Subsidiaries
has the unrestricted right to vote, and (subject to limitations imposed by applicable law) to
receive dividends and distributions on, all capital securities of their respective Subsidiaries.

(s) There are no loans, leases, agreements, contracts, royalty agreements, management
contracts or arrangements or other continuing transactions between (a) the Company, any Subsidiary
or any of their respective customers or suppliers on the one hand, and (b) on the other hand, any
officer, employee, consultant or director of the Company, or any of its Subsidiaries, or any person
owning at least 5% of the outstanding capital stock of the Company or any Subsidiary or any member
of the immediate family of such officer, employee, consultant, director or stockholder or any
corporation or other entity controlled by such officer, employee, consultant, director or
stockholder, or a member of the immediate family of such officer, employee, consultant, director or
stockholder which, in each case, is required to be disclosed in the Commission Documents or in the
Company’s most recently filed definitive proxy statement on Schedule 14A, that is not so disclosed
in the Commission Documents or in such proxy statement.

(t) The records and documents of the Company and its Subsidiaries accurately reflect in all
material respects the information relating to the business of the Company and the Subsidiaries, the
location and collection of their assets, and the nature of all transactions giving rise to the
obligations or accounts receivable of the Company or any Subsidiary. Except as set forth in the
Commission Documents, the Company and each of its Subsidiaries maintain a system of internal
accounting controls sufficient, in the judgment of the Company’s management, to provide reasonable
assurance that (i) transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain asset
accountability, (iii) access to assets is permitted only in accordance with management’s general or
specific authorization and (iv) the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate actions are taken with respect to any
differences.

(u) The Company is in compliance with the applicable provisions of the Sarbanes-Oxley Act of
2002, and the rules and regulations promulgated thereunder.

(v) The Company is not in violation of the listing requirements of the Nasdaq Global Market
and has no knowledge of any facts which would reasonably lead to delisting or suspension of its
common stock in the foreseeable future.

(w) The Warrant when issued and delivered will be duly and validly issued and will be free of
all liens and restrictions on transfer other than any restrictions on transfer under the Securities
Act of 1933, as amended (the “Securities Act”).

(x) The Warrant Shares have been duly reserved for issuance by the Company in sufficient
number to cover the exercise of all of the Warrants. The issuance of the Warrant Shares upon
exercise of the Warrant has been duly authorized by the Company and the Warrant Shares when
delivered in accordance with the Warrant, will be validly issued, fully paid and non-assessable,
and free of all liens and restrictions on transfer other than any restrictions on transfer under
the Securities Act.

(y) The offer, issuance, sale and delivery of the Warrant and Warrant Shares will not under
current laws and regulations require compliance with the prospectus delivery or registration
requirements of the Securities Act.

SECTION 10. Affirmative Covenants.

(a) The Company and each Subsidiary shall maintain its existence and authority to conduct its
business as presently contemplated to be conducted;

(b) The Company shall comply, and cause each Subsidiary to comply, with all applicable laws,
rules, regulations and orders applicable to the Company and each Subsidiary;

(c) The Company shall keep and cause each Subsidiary to keep adequate records and books of
account, in which complete entries will be made in accordance with GAAP consistently applied,
reflecting all financial transactions of the Company and its Subsidiaries, and in which, for each
fiscal year, all proper reserves for depreciation, depletion, obsolescence, amortization, taxes,
bad debts and other purposes in connection with its business shall be made;

(d) The Company shall not enter into any agreement in which the terms of such agreement would
restrict or impair the right or ability to perform of the Company or any Subsidiary under this
Note;

(e) The Company and its Subsidiaries shall maintain insurance with responsible companies in
such amounts and against such risks as is currently carried by the Company and its Subsidiaries;

(f) Company shall pay all applicable taxes as they come due;

(g) The Company shall maintain its listing on the Nasdaq Global Market and neither the Company
nor any of its Subsidiaries shall take any action which would be reasonably expected to result in
the delisting or suspension of the Company’s common stock on the Nasdaq Global Market.

(h) The net proceeds from this Note shall be used by the Company for general corporate
purposes, which may include additions to working capital;

(i) The Company shall timely file all reports required to be filed with the Commission
pursuant to the Exchange Act, and the Company shall not terminate its status as an issuer required
to file reports under the Exchange Act even if the Exchange Act or the rules and regulations
thereunder would permit such termination; and

(j) If the Company shall at any time offer to sell Equity Securities to any person other than
the Noteholder, then the Company shall ensure that the Noteholder will be permitted to participate
(the “Participation Right”) on a pro rata basis in any such offering until the later of (A) one
year from the execution of this Note or (B) such time when this Note is no longer outstanding. For
the purposes hereof, the Noteholder shall be able to include all shares and warrants (assuming the
exercise therof) owned in any pro rata calculation with respect to this paragraph as of the closing
date of any such offering. The term “Equity Securities” shall mean (i) any shares of any class of
capital stock of the Company, and (ii) any debt or equity outstanding or similar instrument
convertible into or exercisable or exchangeable for, with or without consideration, any shares of
any class of capital stock of the Company. Notwithstanding the foregoing, the Participation Right
shall not apply to any offering for the sole purpose of issuing Equity Securities: (i) to
directors, officers, employees, consultants, advisors or other service providers, (ii) pursuant to
the conversion or exercise of convertible or exercisable securities outstanding on the date hereof,
(iii) in connection with a bona fide acquisition of or by the Company, whether by merger,
consolidation, sale of assets, sale or exchange of stock or otherwise, (iv) in connection with any
stock split, stock dividend, recapitalization, reclassification or similar event, (v) to banks,
financial institutions, leasing companies, or other credit providers solely for the purposes of
obtaining credit or lease financing or debt securities or securitizations, and (vi) to strategic or
commercial partners or persons or entities with which the Company has business relationships.

If after the Company has delivered to the Noteholder a notice (the “Notice”) stating its
intention to offer Equity Securities, the number of Equity Securities offered to the Noteholder to
maintain its pro rata share of all Equity Securities, and the price and terms relating thereto,
Noteholder does not elect to purchase all of Noteholder’s pro rata share of all Equity Securities
by written notice received by the Company within three (3) days of the Company having delivered the
Notice to the Noteholder, the Company shall be free to offer the remaining portion of Noteholder’s
pro rata share of all Equity Securities to any other person or entity.

SECTION 11. Negative Covenants.

(a) Neither the Company nor any Subsidiary shall sell, transfer or otherwise dispose of any of
its properties, assets and rights including, without limitation, its software and intellectual
property, to any person except for sales of obsolete assets and sales to customers in the ordinary
course of business or with the prior written consent of the Noteholder;

(b) Neither the Company nor any Subsidiary will become a party to any transaction with any
person who is an affiliate of the Company or any Subsidiary, except transactions in the ordinary
course of business or upon fair and reasonable terms that are fully disclosed to the Noteholder and
are no less favorable to the Company or such Subsidiary than would be obtained in a comparable
arm’s length transaction with a person not an affiliate of the Company or such Subsidiary;

(c) Neither the Company nor any Subsidiary shall merge or consolidate with any other person or
entity, or sell or transfer all or substantially all of its assets without prior written consent of
the Noteholder; and

(d) Neither the Company nor any of the Subsidiaries will liquidate or dissolve or instruct or
grant resolutions to any liquidator of the Company or any Subsidiary.

SECTION 12. Transfers.

The Company may not transfer or assign this Note nor any right or obligation hereunder to any
person or entity without the prior written consent of the Noteholder. The Noteholder may transfer
or assign this Note without the prior consent of the Company.

SECTION 13. Powers And Remedies Cumulative; Delay Or Omission Not Waiver Of Event Of Default.

No right or remedy herein conferred upon or reserved to the Noteholder is intended to be
exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted
by law, be cumulative and in addition to every other right and remedy given hereunder or now or
hereafter existing at law or in equity or otherwise. The assertion or employment of any right or
remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any
other appropriate right or remedy.

No delay or omission of the Noteholder to exercise any right or power accruing upon any Event
of Default occurring and continuing as aforesaid shall impair any such right or power or shall be
construed to be a waiver of any Event of Default or an acquiescence therein; and every power and
remedy given by this Note or by law may be exercised from time to time, and as often as shall be
deemed expedient, by the Noteholder.

SECTION 14. Modification.

This Note may be modified only with the written consent of both the Company and the
Noteholder.

SECTION 15. Attorneys Fees/Enforcement Costs.

(a) The Company will reimburse the Noteholder for reasonable legal fees and expenses (i) in
connection with the transactions contemplated hereby, including without limitation the negotiation,
documentation and execution of the confidentiality agreement, term sheet, Note and Warrant not to
exceed $30,000 and (ii) any amendments to any of the documents contemplated in (i) above, and

(b) In the event that this Note is collected by law or through attorneys at law, or under
advice therefrom, the Company agrees to pay all costs of collection, including reasonable
attorneys’ fees, whether or not suit is brought, and whether incurred in connection with
collection, trial, appeal, bankruptcy or other creditors’ proceedings or otherwise.

SECTION 16. Indemnification

The Company agrees to indemnify and hold harmless the Noteholder (and their respective
directors, officers, managers, partners, members, shareholders, affiliates, agents, successors and
assigns, (an “Indemnified Party”) from and against any and all losses, liabilities, deficiencies,
costs, damages and expenses (including, without limitation, reasonable attorneys’ fees, charges and
disbursements) incurred by such Indemnified Party as a result of any inaccuracy in or breach of the
representations, warranties or covenants made by the Company herein.

SECTION 17. Miscellaneous.

(a) The parties hereto hereby waive presentment, demand, notice, protest and all other demands
and notices in connection with the delivery, acceptance, performance and enforcement of or any
default under this Note, except as specifically provided herein.

(b) Any provision of this Note which is illegal, invalid, prohibited or unenforceable in any
jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such illegality,
invalidity, prohibition or unenforceability without invalidating or impairing the remaining
provisions hereof or affecting the validity or enforceability of such provision in any other
jurisdiction.

(c) This Note shall bind the Company and its successors and permitted assigns. The rights
under and benefits of this Note shall inure to the Noteholder and its successors and assigns.

(d) The Section headings herein are for convenience only and shall not affect the construction
hereof.

(e) All notices, requests, demands, consents, instructions or other communications required or
permitted hereunder shall in writing and faxed, mailed or delivered to each party at the respective
addresses of the parties, or at such other address or facsimile number as the Company shall have
furnished to Noteholder in writing. All such notices and communications will be deemed effectively
given the earlier of (i) when received, (ii) when delivered personally, (iii) one business day
after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one business
day after being deposited with an overnight courier service of recognized standing or (v) on
receipt of confirmation of delivery.

(f) In the event any interest is paid on this Note, which is deemed to be in excess of the
then legal maximum rate, then that portion of the interest payment representing an amount in excess
of the then legal maximum rate shall be deemed a payment of principal and applied against the
principal of this Note.

THIS NOTE HAS BEEN DELIVERED IN NEW YORK, NEW YORK AND SHALL BE DEEMED TO BE A CONTRACT MADE UNDER
AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAW
PRINCIPLES.

THE COMPANY HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF
THE STATE OF NEW YORK AND OF THE UNITED STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK
FOR THE PURPOSE OF ANY LITIGATION ARISING HEREUNDER. THE COMPANY FURTHER IRREVOCABLY CONSENTS TO
THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR
WITHOUT THE STATE OF NEW YORK. THE COMPANY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF
VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY
SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

BY ITS ACCEPTANCE OF THIS NOTE THE NOTEHOLDER AND THE COMPANY HEREBY KNOWINGLY, VOLUNTARILY AND
INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED
HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS NOTE, OR ANY COURSE OF CONDUCT,
COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE NOTEHOLDER OR THE
COMPANY. THE COMPANY ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT
CONSIDERATION FOR THIS PROVISION AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE
NOTEHOLDER MAKING THE LOAN EVIDENCED HEREBY.

1

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed on the date
indicated above.

STAAR SURGICAL COMPANY

By:     

Name:

Title:

SK 22056 0001 758167 v2

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]